Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(50%)
Terminated
1(50%)

Phase Distribution

Ph not_applicable
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
0.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

active_not_recruiting150%
terminated150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruitingnot_applicable

Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy

NCT03908788
terminatednot_applicable

Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib

NCT03956940

Clinical Trials (2)

Showing 2 of 2 trials
NCT03908788Not Applicable

Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy

Active Not Recruiting
NCT03956940Not Applicable

Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
2